Badanie mające na celu ocenę zdarzeń niepożądanych, zmian w aktywności choroby oraz sposobu, w jaki risankizumab podawany dożylnie i podskórnie przenika przez organizm uczestników pediatrii z umiarkowaną do ciężkiej czynną chorobą Leśniowskiego-Crohna (RISE)
Wieloośrodkowe badanie fazy 3 oceniające farmakokinetykę, skuteczność i bezpieczeństwo risankizumabu przy otwartej indukcji, randomizowanym badaniu podtrzymującym metodą podwójnie ślepej próby i długotrwałym okresie przedłużenia u dzieci (w wieku od 2 do < 18 lat) z Umiarkowanie lub ciężko aktywna choroba Leśniowskiego-Crohna
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: ABBVIE CALL CENTER
- Numer telefonu: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lokalizacje studiów
-
-
-
Brussels, Belgia, 1020
- Rekrutacyjny
- Hospital Universite Enfants Reine Fabiola /ID# 255112
-
Liège, Belgia, 4000
- Rekrutacyjny
- Groupe Sante CHC - Clinique du MontLegia /ID# 255620
-
-
Antwerpen
-
Edegem, Antwerpen, Belgia, 2650
- Rekrutacyjny
- Uza /Id# 255114
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgia, 1200
- Rekrutacyjny
- Cliniques Universitaires UCL Saint-Luc /ID# 255108
-
Jette, Brussels Capital, Belgia, 1090
- Rekrutacyjny
- Universitair Ziekenhuis Brussel /ID# 255109
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgia, 3000
- Rekrutacyjny
- Universitair Ziekenhuis Leuven /ID# 255098
-
-
-
-
-
Plovdiv, Bułgaria, 4002
- Rekrutacyjny
- UMHAT Sveti Georgi EAD /ID# 255386
-
Sofia, Bułgaria, 1606
- Zakończony
- Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
-
Varna, Bułgaria, 9009
- Rekrutacyjny
- UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chiny, 100045
- Rekrutacyjny
- Beijing Children's Hospital /ID# 256081
-
Beijing, Beijing Municipality, Chiny, 100191
- Rekrutacyjny
- Peking University Third Hospital /ID# 255876
-
Kontakt:
- Site Coordinator
- Numer telefonu: +86 010-82266699
-
-
Guangdong
-
Guangzhou, Guangdong, Chiny, 510620
- Rekrutacyjny
- Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
-
Guangzhou, Guangdong, Chiny, 510655
- Rekrutacyjny
- The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
-
-
Henan
-
Zhengzhou, Henan, Chiny, 450018
- Rekrutacyjny
- Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
-
-
Hunan
-
Changsha, Hunan, Chiny, 410007
- Rekrutacyjny
- Hunan Children's Hospital /ID# 255610
-
-
Jiangxi
-
Nanchang, Jiangxi, Chiny, 330006
- Rekrutacyjny
- Jiangxi Provincial Children's Hospital /ID# 255564
-
-
Liaoning
-
Shenyang, Liaoning, Chiny, 110022
- Rekrutacyjny
- Shengjing Hospital of China Medical University /ID# 255563
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 200062
- Rekrutacyjny
- Children's Hospital of Shanghai /ID# 255531
-
Shanghai, Shanghai Municipality, Chiny, 200065
- Rekrutacyjny
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
-
-
-
-
Praha 17
-
Prague, Praha 17, Czechy, 128 00
- Zakończony
- Vseobecna Fakultni nemocnice v Praze /ID# 256096
-
-
Praha 5
-
Prague, Praha 5, Czechy, 150 06
- Zakończony
- Fakultni nemocnice Motol a Homolka /ID# 256547
-
-
-
-
-
Paris, Francja, 75015
- Rekrutacyjny
- AP-HP - Hopital Necker /ID# 255608
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Francja, 37044
- Rekrutacyjny
- CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Francja, 33076
- Rekrutacyjny
- Chu Bordeaux - Hopital Pellegrin /ID# 257060
-
-
Occitanie
-
Toulouse, Occitanie, Francja, 31059
- Rekrutacyjny
- CHU Toulouse - Hopital Paule de Viguier /ID# 255609
-
-
Rhone
-
Bron, Rhone, Francja, 69500
- Rekrutacyjny
- Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
-
-
-
-
-
Madrid, Hiszpania, 28009
- Zakończony
- Hospital Infantil Universitario Nino Jesus /ID# 255012
-
Málaga, Hiszpania, 29011
- Rekrutacyjny
- Hospital Regional Universitario de Malaga /ID# 257553
-
-
A Coruna
-
Ferrol, A Coruna, Hiszpania, 15405
- Rekrutacyjny
- Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
-
-
-
-
North Holland
-
Amsterdam, North Holland, Holandia, 1105 AZ
- Rekrutacyjny
- Amsterdam University Medical Center /ID# 254827
-
-
-
-
Central District
-
Petah Tikva, Central District, Izrael, 4920235
- Rekrutacyjny
- Schneider Children's Medical Center /ID# 254950
-
-
Jerusalem
-
Jerusalem, Jerusalem, Izrael, 91031
- Rekrutacyjny
- Shaare Zedek Medical Center /ID# 254951
-
-
-
-
Aichi-ken
-
Ōbu, Aichi-ken, Japonia, 474-8710
- Rekrutacyjny
- Aichi Children's Health And Medical Center /ID# 272085
-
-
Chiba
-
Kashiwa-shi, Chiba, Japonia, 277-0871
- Rekrutacyjny
- Tsujinaka Hospital - Kashiwanoha /ID# 268409
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Japonia, 830-0011
- Rekrutacyjny
- Kurume University Hospital /ID# 268418
-
-
Gunma
-
Maebashi, Gunma, Japonia, 371-8511
- Rekrutacyjny
- Gunma University Hospital /ID# 270560
-
-
Kumamoto
-
Kumamoto, Kumamoto, Japonia, 861-8520
- Rekrutacyjny
- Japanese Red Cross Kumamoto Hospital /ID# 268586
-
-
Osaka
-
Izumi-Shi, Osaka, Japonia, 594-1101
- Rekrutacyjny
- Osaka Women's and Children's Hospital /ID# 268419
-
-
Saitama
-
Saitama-shi, Saitama, Japonia, 330-8777
- Rekrutacyjny
- Saitama Children's Medical Center /ID# 268410
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japonia, 113-8519
- Rekrutacyjny
- Institute of Science Tokyo Hospital /ID# 269175
-
Fuchu-shi, Tokyo, Japonia, 183-8561
- Rekrutacyjny
- Tokyo Metropolitan Children's Medical Center /ID# 268415
-
Setagaya City, Tokyo, Japonia, 157-8535
- Rekrutacyjny
- National Center For Child Health And Development /ID# 268420
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Rekrutacyjny
- Alberta Children's Hospital /ID# 255357
-
Edmonton, Alberta, Kanada, T6G 1C9
- Rekrutacyjny
- Edmonton Clinic Health Academy /ID# 255361
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- Rekrutacyjny
- BC Children's Hospital /ID# 255359
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Rekrutacyjny
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
-
-
-
-
-
Daegu, Korea Południowa, 41404
- Rekrutacyjny
- Kyungpook National University Chilgok Hospital /ID# 255817
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Korea Południowa, 03080
- Rekrutacyjny
- Seoul National University Hospital /ID# 255318
-
Seoul, Seoul Teugbyeolsi, Korea Południowa, 06351
- Rekrutacyjny
- Samsung Medical Center /ID# 255284
-
Seoul, Seoul Teugbyeolsi, Korea Południowa, 03722
- Rekrutacyjny
- Yonsei University Health System - Severance Hospital /ID# 256976
-
-
-
-
Bavaria
-
Munich, Bavaria, Niemcy, 80337
- Rekrutacyjny
- Dr. von Haunerschen Kinderspital /ID# 255577
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Niemcy, 48149
- Rekrutacyjny
- Universitaetsklinikum Muenster /ID# 256762
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Torun, Kuyavian-Pomeranian Voivodeship, Polska, 87-100
- Zakończony
- Gastromed Sp. z o.o /ID# 255939
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polska, 04-730
- Rekrutacyjny
- Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
-
-
-
-
-
Dorado, Portoryko, 00646
- Rekrutacyjny
- Puerto Rico Health Institute /ID# 255071
-
San Juan, Portoryko, 00909-1711
- Rekrutacyjny
- Clinical Research Puerto Rico /ID# 266479
-
-
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85016-7710
- Rekrutacyjny
- Phoenix Children's Hospital /ID# 255766
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72202
- Zakończony
- Arkansas Children's Hospital /ID# 255762
-
-
California
-
Oakland, California, Stany Zjednoczone, 94609
- Rekrutacyjny
- UCSF Benioff Children's Hospital - Oakland /ID# 258327
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- Children's Hospital Colorado - Aurora /ID# 255764
-
-
Florida
-
Orlando, Florida, Stany Zjednoczone, 32806-1141
- Rekrutacyjny
- Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Rekrutacyjny
- Indiana University Health Riley Hospital for Children /ID# 256454
-
-
Massachusetts
-
Waltham, Massachusetts, Stany Zjednoczone, 02451
- Rekrutacyjny
- Massachusetts General Hospital - Mass General Waltham /ID# 255767
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55413-2195
- Rekrutacyjny
- MNGI Digestive Health, P. A. /ID# 255366
-
-
New Jersey
-
Morristown, New Jersey, Stany Zjednoczone, 07960
- Rekrutacyjny
- Goryeb Childrens Hospital /ID# 256452
-
-
New York
-
New York, New York, Stany Zjednoczone, 10029
- Rekrutacyjny
- Icahn School of Medicine at Mount Sinai /ID# 254880
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Rekrutacyjny
- Cleveland Clinic - Cleveland /ID# 256453
-
Kontakt:
- Site Coordinator
- Numer telefonu: 216-636-2007
-
-
-
-
-
Bern, Szwajcaria, 3010
- Rekrutacyjny
- Inselspital, Universitaetsspital Bern /ID# 255321
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Szwajcaria, 8032
- Rekrutacyjny
- Kinderspital Zurich - Eleonorenstiftung /ID# 255337
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Szwecja, 118 83
- Rekrutacyjny
- Sodersjukhuset /ID# 255239
-
Stockholm, Stockholm County, Szwecja, 171 76
- Rekrutacyjny
- Astrid Lindgrens Barnsjukhus /ID# 255240
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Szwecja, 413 46
- Rekrutacyjny
- Sahlgrenska Universitetssjukhuset /ID# 255236
-
Kontakt:
- Site Coordinator
- Numer telefonu: +46313435865
-
-
-
-
-
Changhua City, Changhua County, Tajwan, 50006
- Rekrutacyjny
- Changhua Christian Hospital /ID# 256082
-
Taipei, Tajwan, 100
- Rekrutacyjny
- National Taiwan University Hospital /ID# 255679
-
-
-
-
-
Ankara, Turcja (Türkiye), 06560
- Rekrutacyjny
- Gazi University Medical Faculty /ID# 255086
-
Istanbul, Turcja (Türkiye), 34453
- Rekrutacyjny
- Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
-
Istanbul, Turcja (Türkiye), 34899
- Rekrutacyjny
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
-
Kocaeli, Turcja (Türkiye), 41380
- Rekrutacyjny
- Kocaeli University Med Faculty /ID# 256922
-
-
-
-
-
Messina, Włochy, 98125
- Rekrutacyjny
- Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
-
-
Genova
-
Genoa, Genova, Włochy, 16147
- Rekrutacyjny
- IRCCS Istituto Giannina Gaslini /ID# 255262
-
-
Napoli
-
Naples, Napoli, Włochy, 80131
- Rekrutacyjny
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
-
-
Roma
-
Rome, Roma, Włochy, 00165
- Rekrutacyjny
- Ospedale Pediatrico Bambino Gesu /ID# 255043
-
-
-
-
-
Birmingham, Zjednoczone Królestwo, B4 6NH
- Rekrutacyjny
- Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
-
-
England
-
Sheffield, England, Zjednoczone Królestwo, S10 2TH
- Rekrutacyjny
- Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
-
Kontakt:
- Site Coordinator
- Numer telefonu: +44 114 273 0522
-
-
Greater London
-
London, Greater London, Zjednoczone Królestwo, E1 2ES
- Rekrutacyjny
- Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Pediatric individuals, 2 to < 18 years old
- Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
- Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
- Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Exclusion Criteria:
-
History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
-
Any of the following medical disorders:
-
Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
-
A diagnosis of CD prior to 2 years of age.
-
A diagnosis or suspected diagnosis of a primary immunodeficiency.
-
Currently known complications of CD such as:
- Active abscess (abdominal or perianal);
- Symptomatic bowel strictures;
- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
- Fulminant colitis;
- Toxic megacolon;
- Or any other manifestation that might require surgery while enrolled in the study.
-
Ostomy or ileoanal pouch.
-
Diagnosis of short gut or short bowel syndrome.
-
Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.
-
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Poczwórny
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: PK Cohort 1: SS3 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 1: SS3 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 1: SS1
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 1: SS2 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 1: SS2 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
|
Eksperymentalny: Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Inne nazwy:
Subcutaneous (SC) Injection
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Ramy czasowe: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Ramy czasowe: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Ramy czasowe: Up to approximately Week 64
|
Cmax of risankizumab |
Up to approximately Week 64
|
|
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Ramy czasowe: Up to approximately 64 weeks
|
Tmax of risankizumab |
Up to approximately 64 weeks
|
|
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Ramy czasowe: Up to approximately 64 weeks
|
AUCtau of risankizumab |
Up to approximately 64 weeks
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Ramy czasowe: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Ramy czasowe: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Ramy czasowe: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Ramy czasowe: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Ramy czasowe: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Ramy czasowe: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Ramy czasowe: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Ramy czasowe: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Ramy czasowe: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Ramy czasowe: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Ramy czasowe: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Ramy czasowe: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: ABBVIE INC., AbbVie
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- M16-194
- 2022-502050-14-00 (Inny identyfikator: EU CT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Ramy czasowe udostępniania IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Kryteria dostępu do udostępniania IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .